skip to Main Content

December 15, 2022
Risk of Breakthrough COVID-19 Infections and Disease in Vaccinated People with HIV
This fact sheet on breakthrough COVID-19 infections among people living with HIV was co-produced by TAG and our partners the Black AIDS Institute, Southern AIDS Coalition and the COVID-19 Prevention Network.

December 8, 2022
2022 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

September 16, 2022
COVID-19 and Monkeypox: When Will They End?
Webinar / Presentation
With the emergence of MPV and the existing COVID-19 pandemic, there is growing concern amongst communities broadly on what the future holds. On September 29, please join Treatment Action Group, Black AIDS Institute, and the Coronavirus Prevention Network (CoVPN) with special guests Dr. Demetre Daskalakis, Justin James (Twitter: @TheKingOfReads), and…

August 23, 2022
Treatment Action Group Adds Three New Board Members
Statement / Press
As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

June 23, 2022
Treatment Action Group Statement on NYC DOHMH Monkeypox Vaccination Announcement
Statement / Press
In response to this morning’s announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group’s Executive Director, Mark Harrington, and TAG HIV Project Director…

June 17, 2022
Letter to WTO Condemning Failure to Waive IP Rules
Letter / Comment
TAG and 300 NGOs worldwide condemn the U.S., U.K., E.U., & Switzerland for blocking an intellectual property waiver for purposes of global COVID-19 vaccine production. In light of this shameful failure, we urge countries to act outside of WHO structures to save lives.

June 9, 2022
Lessons Learned from HBCU Responses to the COVID-19 Pandemic
Please join us on June 30 for this free webinar where we discuss the lessons learned from COVID-19 protocols and policies implemented by HBCUs, along with student perspectives that will help inform responses to future pandemics or other public health emergencies.

June 7, 2022
Test and Treat COVID-19: An Advocate’s Introduction to SARS-CoV-2 Rapid Diagnostic Testing
All people have the right to know their COVID-19 status and to be able to use that information to protect themselves, their families, and their communities. Rapid antigen tests can be used at home or in informal settings to reliably and quickly detect cases of COVID-19, to guide decisions on…

June 3, 2022
2021 Annual Report
This year we celebrate the unending dedication and accomplishments of TAG’s staff. They persevered through the challenges of an ongoing pandemic in 2021 to find new ways to carry out our work.

April 20, 2022
Test and Treat COVID-19: Community Guide to Molnupiravir
This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about molnupiravir: what it is, how to take it, who should use it (and who should not,) and how it interacts with other drugs.

April 13, 2022
TAG Submission to WHO Public Hearing Regarding a New International Instrument on Pandemic Preparedness and Response
Letter / Comment
At the first of these two public hearings TAG submitted the following statement with six reasons why the new international instrument must explicitly acknowledge the right to science as a central guiding framework.

April 11, 2022
Test and Treat COVID-19: Community Guide to Paxlovid
Paxlovid can reduce the risk of hospitalization or death by 89% when taken shortly after testing positive for COVID-19. This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about Paxlovid: what it is, who should use it, how to take it, and how…

March 3, 2022
Talk About It with TAG: The Impact of Long COVID on People Living With HIV
Webinar / Presentation
On March 3, 2022, we presented the first “Talk About It with TAG” webinar. This series addresses the needs of community members by having open discussions with researchers and community experts on issues related to COVID-19 and HIV biomedical research.

February 23, 2022
Mourning Paul Farmer, Honoring His Legacy
Statement / Press
TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.

February 15, 2022
Submission to the Office of the High Commissioner for Human Rights Input to HRC resolution 47/17
Letter / Comment
On February 9, TAG submitted this testimony to the Office of the High Commission for Human Rights (OHCHR) to inform its upcoming report to the Human Rights Council (HRC) on ‘human rights in the context of HIV/AIDS’ (HRC resolution 47/17).

December 16, 2021
2021 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

October 19, 2021
TAG and COVID-19 Prevention Network Fact Sheets
These three fact sheets were developed by TAG in partnership with the COVID-19 Prevention Network (CoVPN) and the Black AIDS Institute (BAI), and they aim to foster community understanding of COVID-19 vaccine research and development, as well as highlight community perspectives on the topic.

October 14, 2021
Time for $5 Coalition Urges Cepheid to Reinstate Plans to Launch GeneXpert Omni
Letter / Comment
The civil society Time for $5 Coalition calls out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urges the company to reinstate plans to launch Omni.

September 15, 2021
Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies
GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.

August 31, 2021
Does Delta Mean Change? Community Update on the Delta Variant
Webinar / Presentation
On August 31, 2021, Treatment Action Group (TAG) and Black AIDS Institute (BAI) held a community discussion to get the latest updates on the impact of the Delta variant.

June 4, 2021
2020 Annual Report
As the HIV epidemic changes over time, and new pandemics continue to emerge, TAG continues to evolve while remaining true to our activist roots. We partner with the most affected communities in the U.S. and around the world.

June 3, 2021
TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies
Statement / Press
The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.

May 19, 2021
Breaking Barriers: Surveying Community Perspectives of COVID-19 Vaccine Research
This report aims to raise the profile of discussions that have been taking place regarding community understanding and involvement in COVID-19 vaccine research. It presents the results of an online survey developed by TAG, along with the Black AIDS Institute and the COVID-19 Prevention Trials Network in the fall of 2020…

May 11, 2021
Unique Barriers to COVID-19 Vaccine Access for Black Communities
Webinar / Presentation
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.

May 10, 2021
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
Statement / Press
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

May 6, 2021
TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access
Statement / Press
Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.

April 29, 2021
Addressing Barriers to Engagement with Faith Communities and COVID-19 Research and Vaccine Uptake
On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community…

April 13, 2021
Civil Society Letter to New WTO Director General: Access to COVID-19 Medical Products
Letter / Comment
TAG joined over 200 other civil society signatories in calling for Dr. Ngozi Okonjo-Iweala, incoming Director General of the World Trade Organization, to move away from interventions to scale up global vaccine supplies for COVID-19 that emphasize biopharmaceutical control of vaccine production and eschew public transparency.

April 6, 2021
Community Update on Current and Future COVID-19 Vaccine Trials
On Tuesday, April 6th Treatment Action Group (TAG) hosted a webinar for community advocates with a status update on current and future COVID-19 vaccine trials and answers to questions related to safety and efficacy data.

April 1, 2021
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
Letter / Comment
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for…

Back To Top